Running a successful early-stage biotech company requires a careful balance of enterprise and discipline. Companies must develop disruptive new discovery technologies or insights into disease biology that can have broad applications, but they must choose their first disease application(s) carefully. This tension is in large part driven by the demands around financing a biotech startup so that it can advance through the clinic.
We’ve built Alloy Discovery Services to augment discovery teams’ knowledge in a particular area or give them capacity where they need it. We run comprehensive discovery campaigns to give our partners the best candidate against a particular target of interest, with a robust data package. This service gives smaller teams the opportunity to maximize impact on their journey to the clinic.
We’ve partnered with several companies that we describe as target-rich biotechs: their discovery platforms and insights have generated far more opportunities for drug programs than they are currently able to prosecute, primarily due to bandwidth or modality-specific expertise. Our integrated, in-house venture studio, 82VS offers us a unique opportunity to collaborate with these companies through the creation of joint ventures.
Our joint venture partners identify the targets while Alloy provides discovery services to generate therapeutic candidates, as well as company creation services to support the launch of these companies. These asset-centric joint ventures operate efficiently, with a focus on advancing drug programs, without having to raise the capital required of many early-stage biotech companies.
We’ve launched Broadwing Bio in partnership with Maze Therapeutics, to advance biologic treatments against genetically validated ophthalmology targets generated by Maze’s human genetics and functional genomics platform. Similarly, after an initial ATX-Gx™ License and Alloy Discovery Services relationship with Pyxis Oncology, we teamed up to launch Voxall Therapeutics to prosecute a pipeline of drugs against novel oncology and immunology treatments.
We recognize the innovation coming out of biotech companies often far outpaces the capital that can support it, and we are excited to partner with these companies to allow efficient asset-centric companies to move promising treatments to the clinic. To learn more about building a joint venture with Alloy, please connect with our business development team here.
